Technology
Health
Biotechnology
Audentes Therapeutics
$33.889876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.
$33.88
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
+$0.93 (2.82%) Today
$0.00 (0.00%) As of 4:00 PM EDT after-hours
Why Robinhood?
You can buy or sell BOLD and other stocks, options, ETFs, and crypto commission-free!
About BOLD
Audentes Therapeutics, Inc. Common Stock, also called Audentes Therapeutics, is a biotechnology company, which engages on development and commercialization of gene therapy products for patients with serious and rare diseases caused by single gene defects. Read More Its products include AT001 for the treatment of X-Linked Myotubular Myopathy, AT002 for the treatment of Pompe disease, and AT003 for the treatment of Catecholaminergic Polymorphic Ventricular Tachycardia. The company was founded by Matthew R. Patterson and Thomas J. Schuetz on November 13, 2012 and is headquartered in San Francisco, CA.
Employees
207
Headquarters
San Francisco, California
Founded
2012
Market Cap
1.54B
Price-Earnings Ratio
—
Dividend Yield
0.00
Average Volume
357.83K
High Today
$33.97
Low Today
$32.80
Open Price
$33.36
Volume
333.99K
52 Week High
$41.65
52 Week Low
$17.95
Collections
Technology
Health
Biotechnology
Therapy
2016 IPO
US
North America
BOLD News
Price Paid on Robinhood
13% Higher
Right Now
52 Week Low
$17.95
Average Price Paid
$29.88
52 Week High
$46.18
Analyst Ratings
75%
of 12 ratings
Buy
75%
Hold
17%
Sell
8%
BOLD Earnings
-$1.13
-$1.00
-$0.87
-$0.74
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Q2 2019
Estimated
-$1.03 per share
Actual
-$1.01 per share